GlaxoSmithKline: Pulmonary Disease, Chronic Obstructive trials

The registry lists 276 Pulmonary Disease, Chronic Obstructive studies with GlaxoSmithKline as lead sponsor. 7 are open to participants now and 141 have results posted.

Phase 1 84Phase 2 47Phase 3 65Phase 4 38No phase 43(a study in two phases counts in both)

Studies

Page 1 of 3. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Assess the Efficacy and Safety of Co-administration of GSK3862995B With GSK5784283 in Adult Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)Not yet recruitingNCT07915791Phase 2
• A Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Two GSK3862995B Formulations in Healthy ParticipantsRecruitingNCT07789899Phase 1
• A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-1)RecruitingNCT07780669Phase 3
• A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-2)RecruitingNCT07780656Phase 3
• eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 InflammationRecruitingNCT07177339Phase 3
• Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)RecruitingNCT06961214Phase 3
• Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 InflammationRecruitingNCT06959095Phase 3
• Phase 1, Single and Repeat Dose Study to Assess Safety, Tolerability, and Pharmacokinetics (PK) of GSK3923868 in Participants With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT05677347Phase 1Results posted
• To Evaluate Real-World Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol (FF/UMEC/VI) in a Single Inhaler (Trelegy Ellipta) in Participants With Symptomatic COPDCompletedNCT05535972Phase 4Results posted
• A Study to Evaluate the Safety and Efficacy of Fluticasone Furoate (FF)/Umeclidinium(UMEC)/Vilanterol (VI) in Participants With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT04923347Phase 4Results posted
• Chronic Obstructive Pulmonary Disease (COPD) Maintenance Treatment Patterns in ChinaCompletedNCT04853238Results posted
• Investigation of Chronic Obstructive Pulmonary Disease (COPD) Phenotypes and Endotypes in ChinaCompletedNCT04853225Results posted
• Triple Therapy in Chronic Obstructive Pulmonary Disease (COPD) ParticipantsCompletedNCT04657211Results posted
• Safety, Tolerability and Pharmacokinetics of GSK3923868 Inhalation Powder in Healthy Participants and Stable AsthmaticsCompletedNCT04585009Phase 1Results posted
• Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil LevelCompletedNCT04133909Phase 3Results posted
• Study to Assess the Immunogenicity and Safety of GSK's Investigational Vaccine (GSK3277511A) When Given to Healthy Smokers and Ex-smokers After Administration of Shingrix VaccineCompletedNCT03894969Phase 2Results posted
• Chronic Obstructive Pulmonary Disease (COPD) Dual Therapy Burden of IllnessCompletedNCT03543176Results posted
• A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT03478696Phase 4Results posted
• A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT03478683Phase 4Results posted
• A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT03474081Phase 4Results posted
• INTREPID: Investigation of TRELEGY Effectiveness: Usual Practice DesignCompletedNCT03467425Phase 4Results posted
• GSK1325756 Relative Bioavailability Study in Healthy Elderly SubjectsCompletedNCT03457727Phase 1Results posted
• A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics (PK) of NemiralisibCompletedNCT03398421Phase 1Results posted
• Study to Evaluate the Safety and Efficacy of 13 Weeks of the Selective Androgen Receptor Modulator (SARM) GSK2881078 in Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT03359473Phase 2Results posted
• Sensor and Electronic Health Records (EHR) Integration Pilot StudyCompletedNCT03357341Results posted
• Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)TerminatedNCT03345407Phase 2Results posted
• Absorption & Elimination of Radiolabelled GSK2269557CompletedNCT03315559Phase 1Results posted
• A Study to Test if the Vaccine is Working Well in Chronic Obstructive Pulmonary Disease (COPD) Patients Aged 40 to 80 Years Old to Reduce Episodes of Worsening Symptoms and to Gather Further Information on Safety and Immune Response.CompletedNCT03281876Phase 2Results posted
• Randomized Study Evaluating the Effect of Danirixin on Neutrophil Extracellular Traps (NETs) in Chronic Obstructive Pulmonary Disease (COPD)TerminatedNCT03250689Phase 2Results posted
• Study of Safety and Drug Levels of CCI15106 Inhalation Powder in Healthy Adults and Adults With Moderate Chronic Obstructive Pulmonary Disease. Study of CCI15106 Levels in People Standing Near the Person Inhaling the DrugCompletedNCT03235726Phase 1Results posted
• Comparative Study of ELLIPTA Dry Powder Inhaler (DPI) Versus DISKUS DPI Used With HandiHaler DPI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT03227445Phase 4Results posted
• Safety, Tolerability and Pharmacokinetics (PK) Study of GSK2269557 in Healthy SubjectsCompletedNCT03189589Phase 1Results posted
• A Pilot Study of Danirixin for Disease Progression in Chronic Obstructive Pulmonary Disease (COPD)TerminatedNCT03170232Phase 2Results posted
• Occurrence of Potential Bacterial and Viral Pathogens in Stable Chronic Obstructive Pulmonary Disease and During Acute Exacerbations of the Disease, in Asia PacificCompletedNCT03151395Not applicableResults posted
• Study of Danirixin in Japanese Healthy Elderly Male SubjectsCompletedNCT03136380Phase 1Results posted
• Comparative Study of Error Rates Between ELLIPTA® Dry Powder Inhaler (DPI) and Other DPIsCompletedNCT03114969Results posted
• Danirixin Dose Ranging Study in Participants With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT03034967Phase 2Results posted
• A 24-week Study to Compare Umeclidinium/Vilanterol (UMEC/VI), UMEC and Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT03034915Phase 4Results posted
• A Clinical Study Assessing Critical Errors, Training/Teaching Time, and Preference Attributes of the ELLIPTA® Dry Powder Inhaler, in Comparison to Combinations of Dry Powder Inhalers Used to Provide Triple Therapy, in Patients With Chronic Obstructive Pulmonary DiseaseCompletedNCT02982187Phase 4Results posted
• An Efficacy Study of Umeclidinium/Vilanterol With Tiotropium/Olodaterol in COPD PatientsCompletedNCT02799784Phase 4Results posted
• Preference Attributes of ELLIPTA Dry Powder Inhaler (DPI) and HANDIHALER DPI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02786927Phase 4Results posted
• Comparative Study of Fluticasone Furoate(FF)/Umeclidinium Bromide (UMEC)/ Vilanterol (VI) Closed Therapy Versus FF/VI Plus UMEC Open Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02729051Phase 3Results posted
• Ease of Use and Correct Use Study of Placebo ELLIPTA® Inhaler in COPD SubjectsCompletedNCT02586493Phase 4Results posted
• Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary DiseaseCompletedNCT02573870Phase 2Results posted
• Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02570165Phase 2Results posted
• A Study to Investigate the Efficacy, Safety, and Tolerability of Repeat Doses of Inhaled GSK2269557 in Adults With Persistent, Uncontrolled AsthmaCompletedNCT02567708Phase 2Results posted
• A Study to Evaluate the Safety, Efficacy and Changes in Induced Sputum and Blood Biomarkers Following Daily Repeat Doses of Inhaled GSK2269557 in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Acute ExacerbationCompletedNCT02522299Phase 2Results posted
• A Comparison Study Between the Fixed Dose Triple Combination of Fluticasone Furoate/ Umeclidinium/ Vilanterol Trifenatate (FF/UMEC/VI) With Budesonide/Formoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02345161Phase 3Results posted
• Safety and Efficacy Study of Losmapimod (GW856553) in Frequently Exacerbating Participants With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02299375Phase 2Results posted
• An Efficacy Study of GSK2269557 Added to Standard Care in Subjects With an Acute Exacerbation of Chronic Obstructive Pulmonary DiseaseCompletedNCT02294734Phase 2Results posted
• A Study to Evaluate the Effect of the Combination of Umeclidinium (UMEC) and Vilanterol (VI) on Exercise Endurance Time (EET) in Participants With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02275052Phase 4Results posted
• Comparative Study of Umeclidinium/Vilanterol (UMEC/VI) in a Fixed Dose Combination With Indacaterol Plus TiotropiumCompletedNCT02257385Phase 3Results posted
• A Study to Evaluate the Effect of Umeclidinium (UMEC) as Combination Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02257372Phase 4Results posted
• A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium 62.5 Microgram (mcg) Compared With Glycopyrronium 44 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02236611Phase 4Results posted
• A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium Compared With Tiotropium in Subjects With Chronic Obstructive Pulmonary DiseaseCompletedNCT02207829Phase 3Results posted
• Study of Inhaler Device Attributes Investigating Critical and Overall Errors, Ease of Use, and Preference Between a Number of Inhaler DevicesCompletedNCT02184624Phase 4Results posted
• A 24 Week Efficacy Study of Inhaled Umeclidinium (UMEC) in Patients of Chronic Obstructive Pulmonary Disease (COPD) Using a Novel Dry Powder Inhaler (NDPI)CompletedNCT02184611Phase 3Results posted
• Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic ComponentCompletedNCT02164539Phase 2Results posted
• A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02164513Phase 3Results posted
• A Phase IIIb Study to Evaluate the Efficacy of Umeclidinium/Vilanterol (UMEC/VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02152605Phase 3Results posted
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Dose-Response Relationship of Multiple Doses of GSK2269557 Administered as a Dry Powder to Chronic Obstructive Pulmonary Disease (COPD) PatientsCompletedNCT02130635Phase 2Results posted
• Investigation of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for ExacerbationsCompletedNCT02130193Phase 2Results posted
• Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) -Study 2CompletedNCT02119286Phase 3Results posted
• Study Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) Compared With Vilanterol Inhalation Powder (VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02105974Phase 3Results posted
• Efficacy and Safety of Mepolizumab as an Add-on Treatment in Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02105961Phase 3Results posted
• Study to Evaluate Efficacy and Safety of Mepolizumab for Frequently Exacerbating Chronic Obstructive Pulmonary Disease (COPD) PatientsCompletedNCT02105948Phase 3Results posted
• A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GlaxoSmithkline (GSK) Biologicals' Investigational Vaccine GSK2838504A When Administered to Chronic Obstructive Pulmonary Disease (COPD) Patients With Persistent Airflow Obstruction.CompletedNCT02075541Phase 2Results posted
• A Cross-Over Study to Evaluate Lung Function Response After Treatment With Umeclidinium (UMEC) 62.5 Micrograms (mcg), Vilanterol (VI) 25 mcg, and Umeclidinium/Vilanterol (UMEC/VI) 62.5/25 mcg Once-Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02014480Phase 3Results posted
• A Non-inferiority Study to Evaluate the Efficacy, Safety, and Tolerability of Fluticasone Propionate/Salmeterol (FSC) 250/50 Microgram (mcg) Through a Capsule-Based Inhaler and a Multi-Dose Inhaler Administered Twice Daily (BID) in Adults With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01978145Phase 3Results posted
• Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01957163Phase 3Results posted
• Study Evaluating the Effect of Fluticasone Furoate/ Vilanterol (FF/VI) Inhalation Powder Compared With Vilanterol (VI) Inhalation Powder on Bone Mineral Density (BMD) in Subjects With Chronic Obstructive Pulmonary Disease (COPD).CompletedNCT01957150Phase 4Results posted
• The Purpose of the This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotropium 18mcg Once Daily Over a a 12-week Treatment Period in Subjects With COPD Who Continue to Have Symptoms on TiotropiumCompletedNCT01899742Phase 3Results posted
• A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01879410Phase 3Results posted
• DISKUS vs. ELLIPTA Device Preference Study in Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01868009Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Umeclidinium Bromide/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01822899Phase 3Results posted
• A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01817764Phase 3Results posted
• The Purpose of This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotriopium 18 mcg Once Daily Over a 24-week Treatment Period in Subjects With COPDCompletedNCT01777334Phase 3Results posted
• Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.CompletedNCT01772147Phase 3Results posted
• Efficacy and Safety of the Addition of Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide (62.5 or 125mcg) Once-daily Over 12 WeeksCompletedNCT01772134Phase 3Results posted
• Evaluating the Control of COPD Symptoms in Patients Treated With Tiotropium Bromide 18mcg Once Daily Alone, ADOAIR 50/250mcg Twice Daily Alone or ADOAIR 50/250mcg Plus Tiotropium Bromide 18mcgCompletedNCT01762800Phase 4Results posted
• A 3 Way Cross-over Study Evaluating the Effects of ADOAIR Twice Daily Plus Tiotropium Bromide Once Daily Compared With the Individual Treatments of Japanese SubjectsCompletedNCT01751113Phase 4Results posted
• Cross-Over Study in Subjects With COPD, Evaluating Lung Function Response After Treatment With Once Daily Umeclidinium 62.5mcg, Vilanterol 25mcg, and Umeclidinium/Vilanterol 62.5/25mcgCompletedNCT01716520Phase 3Results posted
• A Study to Assess the Efficacy of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01706328Phase 3Results posted
• Long-term Safety Study for GSK573719 in JapaneseCompletedNCT01702363Phase 3Results posted
• RELOVAIR® Lung Deflation StudyCompletedNCT01691885Phase 3Results posted
• A Study to Look at Day to Day Changes in Lung Function in COPD Subjects Taking Albuterol/Salbutamol and IpratropiumCompletedNCT01691482Phase 4Results posted
• A 24-week Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 125/25 mcg and 62.5/25mcg Inhalation Powder Compared With Placebo in Subjects With COPDCompletedNCT01636713Phase 3Results posted
• Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular DiseaseCompletedNCT01627327Phase 3Results posted
• ADOAIR250 Anti-inflammatory Effects in Japanese Subjects With Chronic Obstructive Pulmonary DiseaseCompletedNCT01607398Phase 4Results posted
• A Randomised Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01551758Phase 3Results posted
• Effects of Salmeterol on Autonomic Nervous SystemCompletedNCT01536587Phase 4Results posted
• A Study to Assess Immunity to Specific Microbial Antigens in Healthy Smokers and Non-smokers and in Subjects With Stable COPDCompletedNCT01516437Not applicableResults posted
• Pharmacokinetic and Pharmacodynamic (PK and PD) Study of Fluticasone Propionate and Salmeterol Combination Product Delivered in a Capsule-based Inhaler and in a Multi-dose Dry Powder Inhaler in Moderate Asthma Patients and Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Patients.CompletedNCT01494610Phase 1/2Results posted
• A Study to Compare the Impact of Fulticasone Furoate/Vilanterol vs. Tiotropium on Arterial Stiffness in COPDCompletedNCT01395888Phase 3Results posted
• Evaluate the Efficacy and Safety of GSK573719 Delivered Via a Novel Dry Powder Inhaler in Subjects With COPDCompletedNCT01387230Phase 3Results posted
• Outcomes From Initial Maintenance Therapy With Fluticasone Propionate 250/Salmeterol 50 (FSC) or Tiotropium in Chronic Obstructive Pulmonary DiseaseCompletedNCT01387178Results posted
• Fluticasone Propionate-salmeterol Combination Adherence in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01381471Results posted
• Impact of Initiating Tiotropium Alone Versus Initiating Tiotropium in Combination With Fluticasone Propionate/Salmeterol Xinafoate Combination (FSC) on Chronic Obstructive Pulmonary Disease-related Outcomes in Patients With Pre-existing ExacerbationsCompletedNCT01381406Results posted
• Long-term Safety Study for GSK573719/GW642444 in JapaneseCompletedNCT01376388Phase 3Results posted
• A 24-week Study of Fluticasone Furoate/Vilanterol Inhalation Powder in Subjects of Asian Ancestry With COPDCompletedNCT01376245Phase 3Results posted